James DeMasi
Long only, special situations, growth at reasonable price, contrarian

Special Situations Investing With HART

I recently had the pleasure of speaking to David Green, the CEO of Harvard Apparatus Regenerative Technology (HART). Please listen to that interview here either before or after reading this, as it supplements the content of this article. This company is pre-revenue, so it is not one that I would typically invest in or value. However, I am open to all investment ideas, and this one has a few important exceptions that made me pay attention. Notably, the company has demonstrated proof of concept, holds numerous patents, and is the first mover in a $600 million market all while sporting a tiny market cap.

HART was recently spun off of Harvard Bioscience (NASDAQ:HBIO). The company is currently working...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details